Iberdomide is primarily utilized in the treatment of hematologic malignancies, particularly multiple myeloma. It functions as a cereblon E3 ligase modulator, enhancing the degradation of specific proteins that are crucial for the survival of cancer cells. This mechanism makes it effective in combination therapies, often paired with other agents like dexamethasone or proteasome inhibitors to improve treatment outcomes. Additionally, it is being explored for its potential in autoimmune diseases due to its immunomodulatory properties, which can help regulate abnormal immune responses. Its targeted action and ability to enhance the immune system's ability to fight cancer cells make it a promising candidate in ongoing clinical trials for various cancers and immune-related conditions.